Neuly

FILAMENT Wellness AND CYBIN THERAPEUTICS ANNOUNCE Approval FOR Stage II ...

Jan 31, 2022 – Trial to look into the results of Filament's botanical psilocybin drug prospect and Cybin Therapeutics' protocols in managing significant ...

Psilocybin

Braxia Scientific Provides Update on Large Proprietary Dataset Expected to Support ...

Jan 31, 2022 – ... on Large Proprietary Dataset Expected to Support Pharmaceutical and Industry Clinical Trials for Ketamine and Psilocybin Drug Development.

Psilocybin / Ketamine

filament health and cybin therapeutics announce approval for phase ii clinical trial for depression

Jan 31, 2022 – Trial to investigate the effects of Filament's botanical psilocybin drug candidate and Cybin Therapeutics' protocols in treating major depressive ...

Psilocybin

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Releases Q1 2022 Financial Numbers

Jan 31, 2022 – Tryp's psilocybin-for-neuropsychiatric disorders, or PFN(TM) (“PFN”), program is focused on the development of synthetic psilocybin as a new class of ...

Psilocybin

UPDATE: Filament Health (FH.NE) Receives Approval From Health Canada for Phase 2 Clinical Trial

Jan 31, 2022 – (CYBN.NE), Cybin Therapeutics is a private therapeutic bioscience company committed to developing psilocybin-assisted therapeutic protocols to treat ...

Psilocybin

Braxia Scientific Corp. says it continues psychedelic-based clinical research trials to support ...

Jan 31, 2022 – ... subsidiary has established a growing database with key clinical outcomes for an ongoing clinical trial evaluating psilocybin-assisted therapy.

Psilocybin / Ketamine

Q&A with Dr. Tiffany Sauls, psychiatrist providing psychedelic-assisted psychotherapy ...

Jan 31, 2022 – Today, Sauls provides ketamine-assisted psychotherapy at her integrative psychiatry practice in Asheville. The federal Department of Justice's Drug ...

Ketamine / MDMA

Ketamine clinic for mental health disorders opening in Fitchburg | State & Regional | wiscnews.com

Jan 31, 2022 – Ketamine infusions will be offered to people with major depressive disorder, post-traumatic stress disorder, postpartum depression, suicidal ideation ...

Ketamine

Perceptual studies may explain promising depression treatments - Florida News Times

Jan 31, 2022 – We then tested what happens when we administer small doses of ketamine. Credits: Scott Yu, I. Gauthier, I., MJ Tarr Via Wikimedia Commons.

Ketamine

Why Docs are Legitimately Using Ketamine Therapy to Treat Depression - Medical News Bulletin

Jan 31, 2022 – Fortunately for patients suffering from treatment resistant depression, there are alternative treatment options, such as ketamine.

Ketamine

Perception study may explain promising depression therapy - UW–Madison News

Jan 31, 2022 – Their study reveals the importance of a specific type of connection between brain cells and may also explain ketamine's promise as a treatment for ...

Ketamine

Relieving depression with LSD-like drugs without causing hallucinations | FierceBiotech

Jan 31, 2022 – The hallucination side effect has stalled the use of psychedelics such as LSD and psilocybin from “magic mushrooms” to treat depression.

Psilocybin / LSD

Researchers use linguistic analysis to uncover differences between psychedelic drug experiences

Jan 31, 2022 – The sample included 971 reports about psilocybin-containing mushrooms, 671 reports about LSD, 312 reports about DMT, 163 reports about ketamine, ...

Psilocybin / LSD / DMT / Ketamine / Ayahuasca

Small Pharma Reports Fiscal Third Quarter 2021 Highlights - GlobeNewswire

Jan 31, 2022 – DMT is a naturally occurring psychedelic tryptamine found in plants and in the brain of mammals. Scientific evidence suggests DMT offers the potential ...

DMT / Tryptamine

Pharma to Test if DMT Helps Brain Regain Function Post Stroke - Investorideas.com

Jan 31, 2022 – 27, 2022, representatives of Algernon Pharmaceuticals discussed the use of the psychedelic DMT in stroke sufferers. On the broadcast were Algernon ...

DMT

9th Circ. Won't Review DEA Letter On Medical Psilocybin Use - Law360

Jan 31, 2022 – Psilocybin is a hallucinogenic substance obtained from certain mushrooms and is a Schedule I drug under the CSA, per Monday's opinion.

Psilocybin

Jan 31, 2022 – “MDMA allows you to access these really deep traumatic memories in a way that is not anxiety-provoking,” said Jennifer Mitchell, ...

MDMA

Best 2022 Wellness Trend? Tripping at a Psychedelic Retreat - Thrillist

Jan 31, 2022 – From shrooms to ayahuasca, these wellness hotels are tapping into a new way to help mental health with psychedelic micro-dosing.

Ayahuasca / Psilocybin / LSD / MDMA

Weekly Roundup on the Cannabis Sector & Psychedelic Sector - Market Exclusive

Jan 31, 2022 – Trulieve borrowed additional $75 million at 8%. Key Takeaways; Psychedelic Sector. Awakn filed a patent application for a new class of entactogen-like ...

Leafy Tunnel announces the first closing of its medical cannabis and psychedelics fund

Jan 31, 2022 – The investment strategy of the fund focuses on European medical cannabis and global medical psychedelics companies at Seed and Series A stages.

Cannabis

Colorado Could See two Psychedelic Ballot Measures in November | Westword

Jan 31, 2022 – Get ready, Colorado voters: Come November, there's a chance you may get to decide on not one psychedelics ballot measure, but two.

Psilocybin

atai Life Sciences Launches Invyxis to Accelerate Discovery of Next-Generation Mental Health Treatments

Jan 27, 2022

atai Life Sciences

Numinus Wellness Inc. Graduates to the OTCQX Best Market

Jan 26, 2022

Numinus

Awakn Life Sciences Files Patent Application for a New Class of Entactogen-Like Molecules to Treat a Broad Range of Addictions

Jan 26, 2022

Awakn Life Sciences, Inc.

Filament Health Subsidiary Psilo Scientific Announces Inclusion in Health Canada List of Licensed Psilocybin Producers

Jan 26, 2022

Filament Health

Seattle Legalizes Psychedelics

Jan 25, 2022 – Proponents of the legalization of psychedelics has won a victory. ... Monday to decriminalize a wide range of activities around psychedelic drugs, ...

Psilocybin / Mescaline / Ibogaine / Ayahuasca / Iboga

MINDCURE Announces Financial Results for the Second Quarter of Fiscal 2022

Jan 25, 2022

G2 Buys Peyote-Focused Psychedelics Company Lophos Pharma | Benzinga

Jan 24, 2022 – Greenridez 2.0 Acquisitions Corp. confirmed Friday that it has completed its acquisition of psychedelic research company.

Cover Story: Power Trip: New York Magazine podcast investigates psychedelics | Stuff.co.nz

Jan 22, 2022 – More than ever, people are turning to psychedelics for relief, enlightenment and understanding – think ayahuasca retreats and mushroom ...

Ayahuasca

Have You Taken Psychedelics? Participate In The Canadian Psychedelics Survey ...

Jan 21, 2022 – ... MDMA, ayahuasca, and ketamine, as well as whether participants have ever used certain psychedelics in combination with other drugs.

MDMA / Ketamine / Ayahuasca / Psilocybin

G2 Acquires Lophos Pharma, a peyote focused psychedelics company - GlobeNewswire

Jan 21, 2022 – Lophos Pharma is a psychedelic research company primarily focused on novel therapeutic treatments derived from Peyote (Lophophora williamsii).

Do Ayahuasca Healing Ceremonies Really Work? | Psychology Today

Jan 18, 2022 – In some cases an ayahuasca ceremony may be more effective for treating neuroticism than traditional therapies. Six percent of study participants ...

Ayahuasca

Terminally Ill Patients In Missouri Can Seek Psychedelic Treatments Under 'Right To Try ...

Jan 15, 2022 – ... participating in the right-to-try policy to possess Schedule I drugs such as MDMA, DMT, ibogaine, LSD, mescaline, peyote and psilocybin.

Psilocybin / LSD / Mescaline / DMT / MDMA / Ibogaine / Iboga

Wesana Health Provides Strategic and Operational Updates

Jan 12, 2022

Wesana Health

PharmaTher Announces FDA Approval of Investigational New Drug (IND) Application for Ketamine to Treat ALS

Jan 12, 2022

Pharmather

MYND Life Sciences Announces Collaborative Research Agreement with the University of British Columbia

Jan 12, 2022

MYND Life Sciences Inc.

atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program

Jan 12, 2022